Next Phase Newsletter

An approximately 200 million USD China based venture capital firm currently invests in healthcare (Pharmaceutical, medical device, diagnostics and Health IT) companies exclusively in China. In addition to investing in Chinese companies the firm is actively involved in and seeking to make new partnerships with technologies from around the globe in a number of specific technology areas exclusively for the Chinese market.

On the pharmaceutical end, the firm targets late stage assets post phase IIb to marketed products. For Medical technology products the firm currently holds companies that are looking for orthopedic products (spinal motion preservation and other non-fusion technologies), women’s health medical products, surgical instruments, dental devices and cardiovascular medical devices. On diagnostics, the primary focus is on oncology next generation sequencing systems and reagents; lastly for Health IT, diabetes management hardware.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A virtual pharma company founded in 2010 is currently seeking to in-license assets in the oncology sector, and is open to partnering with companies worldwide. The firm uses a wide variety of partnership structures, depending on the stage of development of the asset in question. The firm assesses therapeutic opportunities regularly and makes a new intake of assets every 1-2 years. The firm is open to working with companies worldwide, but generally focuses on North America and Europe-based opportunities.

The firm is interested in oncology therapeutics with novel mechanisms of action, and is open to working with small molecules and biologics, but not cell therapies. The firm seeks assets at any stage of development, from early preclinical development onward. The firm may also consider partnering with companies developing biomarker diagnostic technologies that guide cancer care decisions. In addition to standalone assets, the firm is interested in potential combinations of oncology treatments in areas such as immuno-oncology, checkpoint inhibitors, and other types of agents with combination potential. The firm will consider opportunities in all cancers, including orphan cancers; the firm’s portfolio currently includes ovarian and breast cancer assets, but other areas of cancer will also be considered, including liquid tumors. The firm is not currently interested in supportive care.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm also willing to consider medical devices targeting these indications.

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment group that was founded by a single family out of Hong Kong has four operations based in Shanghai, Beijing, Hong Kong and the US. The US-based venture investment arm is actively seeking new investments in the life sciences across the US, and it occasionally invests in companies in Europe. The group focuses on pre-clinical and clinical stage companies. The investment size will vary and typically it ranges from $2 million -$10 million. The group has no set number of allocations over the next 6-9 months.

In the life sciences the firm is looking for new investments primarily in the biotech therapeutics sector. The group will also look at medical devices and diagnostics opportunities, however, which are not their current focuses. For therapeutics, the group is most interested in biologics. The group invests in a variety of therapeutic areas with a focus on oncology. The group generally invests in pre-clinical stage companies without clinical data, and it also syndicates with other investors for clinical-stage investments.

The group invests in privately held life science companies. The group is generally not interested in commercial-stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharmaceutical company with offices worldwide uses a wide variety of structures in order to engage with innovative early-stage companies, including in-licensing, equity investments, options, collaborations, and acquisitions. The firm is currently looking to form new partnerships with early stage companies worldwide.

The firm is interested in therapeutic assets in the following key disease areas: cardiovascular, fibrosis, immunology, oncology, virology, and genetically-defined diseases. The firm can invest at any stage of development, from very early discovery-stage assets through to marketed products. The firm is open to any technological approach, but is only interested in novel drugs; biosimilars and reformulations are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company. The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.

The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.

The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A foundation formed to improve the health and quality of life for children has recently begun looking to make equity investment in early stage companies. The foundation’s programs supports pediatric researchers who work in nonprofit academic, medical or research institutions within the six New England states. The foundation is currently developing a new financial vehicle to make program related investment in commercial companies developing technologies that can improve children’s health. The foundation expects to make 1-2 equity allocations of $200,000 in the current year and is seeking opportunities globally.

The foundation is looking for high impact innovations in children’s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com